Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Solid support and method of culturing cells on said solid...
Reexamination Certificate
2007-02-27
2011-10-11
Lankford, Jr., Blaine (Department: 1651)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Solid support and method of culturing cells on said solid...
C514S011800
Reexamination Certificate
active
08034618
ABSTRACT:
Proteins are incorporated into protein or polysaccharide matrices for use in tissue repair, regeneration and/or remodeling and/or drug delivery. The proteins can be incorporated so that they are released by degradation of the matrix, by enzymatic action and/or diffusion. As demonstrated by the examples, one method is to bind heparin to the matrix by either covalent or non-covalent methods, to form a heparin-matrix. The heparin then non-covalently binds heparin-binding growth factors to the protein matrix. Alternatively, a fusion protein can be constructed which contains a crosslinking region such as a factor XIIIa substrate and the native protein sequence. Incorporation of degradable linkages between the matrix and the bioactive factors can be particularly useful when long-term drug delivery is desired, for example in the case of nerve regeneration, where it is desirable to vary the rate of drug release spatially as a function of regeneration, e.g. rapidly near the living tissue interface and more slowly farther into the injury zone. Additional benefits include the lower total drug dose within the delivery system, and spatial regulation of release which permits a greater percentage of the drug to be released at the time of greatest cellular activity.
REFERENCES:
patent: 4086196 (1978-04-01), Tregear et al.
patent: 4613665 (1986-09-01), Larm
patent: 4810784 (1989-03-01), Larm
patent: 5100668 (1992-03-01), Edelman et al.
patent: 5171670 (1992-12-01), Kronenberg et al.
patent: 5202247 (1993-04-01), Kilburn et al.
patent: 5428014 (1995-06-01), Labroo et al.
patent: 5504001 (1996-04-01), Foster
patent: 5510370 (1996-04-01), Hock
patent: 5529986 (1996-06-01), Larsson et al.
patent: 5561982 (1996-10-01), Tunkel et al.
patent: 5582862 (1996-12-01), Reed et al.
patent: 5641670 (1997-06-01), Treco et al.
patent: 5693341 (1997-12-01), Schroeder et al.
patent: 5747456 (1998-05-01), Chorev et al.
patent: 5773577 (1998-06-01), Capello
patent: 5814603 (1998-09-01), Olderburg et al.
patent: 5840837 (1998-11-01), Krstenansky et al.
patent: 5874308 (1999-02-01), Kilburn et al.
patent: 5877153 (1999-03-01), Harris et al.
patent: 5958874 (1999-09-01), Clark et al.
patent: 6054122 (2000-04-01), MacPhee et al.
patent: 6117425 (2000-09-01), MacPhee et al.
patent: 6136564 (2000-10-01), Kopetzki et al.
patent: 6197325 (2001-03-01), MacPhee et al.
patent: 6221854 (2001-04-01), Radomsky
patent: 6331422 (2001-12-01), Hubbell
patent: 6468543 (2002-10-01), Gilbertson et al.
patent: 6468731 (2002-10-01), Hubbell et al.
patent: 6541022 (2003-04-01), Murphy et al.
patent: 6559119 (2003-05-01), Burgess et al.
patent: 6730721 (2004-05-01), Bezemer et al.
patent: 6894022 (2005-05-01), Hubbell et al.
patent: 6960452 (2005-11-01), Hubbell et al.
patent: 7026292 (2006-04-01), Lee et al.
patent: 7045105 (2006-05-01), Lagow
patent: 7052856 (2006-05-01), Ting
patent: 7247609 (2007-07-01), Lutolf et al.
patent: 2002/0146414 (2002-10-01), Sakiyama et al.
patent: 2003/0119186 (2003-06-01), Hubbell et al.
patent: 2003/0180376 (2003-09-01), Dalal et al.
patent: 2003/0187232 (2003-10-01), Hubbell et al.
patent: 2005/0148763 (2005-07-01), Sekimori et al.
patent: 200 10 297 (2000-08-01), None
patent: 7-196925 (1995-08-01), None
patent: WO 89/00051 (1989-01-01), None
patent: WO 90/05177 (1990-05-01), None
patent: WO 92/02620 (1992-02-01), None
patent: WO 92/09301 (1992-06-01), None
patent: WO 92/22312 (1992-12-01), None
patent: WO 94/20133 (1994-09-01), None
patent: WO 95/05396 (1995-02-01), None
patent: WO 95/23611 (1995-09-01), None
patent: WO 96/17633 (1996-06-01), None
patent: WO 97/18314 (1997-05-01), None
patent: WO 97/24445 (1997-07-01), None
patent: WO 98/43686 (1998-10-01), None
patent: WO 99/03887 (1999-01-01), None
patent: WO 99/21588 (1999-05-01), None
patent: WO 99/31137 (1999-06-01), None
patent: WO 00/06534 (2000-02-01), None
patent: WO 00/10596 (2000-03-01), None
patent: WO 00/44808 (2000-08-01), None
patent: WO 00/49159 (2000-08-01), None
patent: WO 00/64481 (2000-11-01), None
patent: WO 01/12230 (2001-02-01), None
patent: WO 01/66164 (2001-09-01), None
patent: WO 01/76558 (2001-10-01), None
patent: WO 01/81415 (2001-11-01), None
patent: WO 01/83522 (2001-11-01), None
patent: WO 03/040235 (2003-05-01), None
Borth, et al., “Lipoprotein (a) is a substrate for factor XIIIa and tissue transglutaminase”,J. Biol. Chem., 266 (27): 18149-18153 (1991).
Hettasch, et al., “Analysis of factor XIII substrate specificity using recombinant human factor XIII and tissue transglutaminase chimeras”,J Biol Chem. , 272(40): 25149-25156 (1997).
Wells, “Additivity of mutational effects in proteins”,Biochemistry, 29(37):8509-8517 (1990).
Gittens, et al. “Designing Proteins for Bone Targeting”,Advanced Drug Delivery Reviews57(7):1-11-1036(2005).
Jagur-Grodzinski, et al. “Biomedical application of functional polymers”,Reactive Polymers39(2):99-138(1999).
Luginbuehl, et al. “Localized Delivery of Growth Factors for Bone Repair”,Eur. J. of Pharm. And Biopharm. 58(2):197-208(2004).
Gupta, et al., “Arterial vimentin is a transglutaminase substrate: a link between vasomotor activity and remodeling?”,J. Vas. Res., 44(5):339-344 (2007).
Kahlem, et al., “Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: relevance to diseases of the nervous system”,Proc. Natl. Acad. Sci. USA, 93(25):14580-14585 (1996).
Uhlèn, et al., “Fusion proteins in biotechnology”,Current Opinion in Biotechnology, 3(4):363-9 (1992).
Adams, et al., “Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis,”Genes&Development, 13:295-306 (1999).
Baumgartner, et al., “Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia,”Circulation, 97:1114-1123 (1998).
Besson, et al., “Synthetic peptide substrates for a conductimetric assay ofPseudomonas aeruginosaelastase,”Analytical Biochemistry237(0232):216-223 (1996).
Blaess, et al., “Structural analysis of the sixth immunoglobulin-l ike domain of mouse neural cell adhesion molecule L1 and its interactions with v3, IIb3, and 51 integrins,”J Neurochem, 71:2615-2625 (1998).
Borrajo, et al., “Derivatized Cyclodextrins as peptidometics: Influence on Neurite Growth,”Bioorganic and Medicinal Chemistry Letters7:1185-90 (1997).
Brooks, et al., “Requirement of vascular integrin v3 for angiogenesis,”Science, 264:569-571 (1994).
Bruckner, “EphrinB ligands recruit GRIP family PDZ adaptor proteins into raft membrane microdomains,”Neuron, 22:511-524 (1999).
Calderwood, et al., “Integrins and actin filaments: reciprocal regulation of cell adhesion and signaling,”J Biol Chem, 275:22607-22610 (2000).
Camarata, et al., “Sustained Release of Nerve Growth Factor from Biodegradable Polymer Microspheres,”Neurosurgery, 30(3)313-319 (1992).
Cardin, et al., “Molecular Modeling of Protein-Glycosaminoglycan Interactions,”Arteriosclerosis9:21-32 (1989).
Conover, et al., “Disruption of Eph/ephrin signaling affects migration and proliferation in the adult subventricular zone,”Nature Neuroscience3(11):1091-3324 (2000).
Coombs, et al. “Directing sequence-specific proteolysis to new targets. The influence of loop size and target sequence on selective proteolysis by tissue-type plasminogen activator and urokinase-type plasminogen activator,”J. Biol. Chem. 273(8):4323-8 (1998).
Dalva, et al., “EphB receptors interact with NMDA receptors and regulate excitatory synapse formulation,”Cell103:945-956 (2000).
Dedhar & Hannigan, “Integrin cytoplasmic interactions and bidirectional transmembrane signaling,”Current Opinion in Cell Biology8:657-669 (1996).
Dimilla, et al., “Mathematical model f
Hubbell Jeffrey A.
Jen Anna
Lutolf Matthias
Schense Jason C.
Eldgenossische Technische Hochschule Zurich
Lankford, Jr. Blaine
Pabst Patent Group LLP
Universitat Zurich
LandOfFree
PTH containing cell growth matrix does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PTH containing cell growth matrix, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PTH containing cell growth matrix will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4260879